Published Date: 09 Jun 2023
According to a recent study by Nicholas Phillips and colleagues, adult cancer survivors are more likely to experience modifiable late-onset memory impairment.
Read Full NewsResearchers at The University of Texas MD Anderson Cancer Center, in collaboration with BostonGene, conducted the largest and most comprehensive molecular analysis of renal medullary carcinoma (RMC), a rare and aggressive ...
The U.S. Food and Drug Administration approved Blenrep (belantamab mafodotin-blmf) in combination with bortezomib and dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma.
1.
Adult survivors of childhood cancer are at high risk for cognitive impairment, according to JAMA.
2.
Durvalumab Wins FDA Approval in Limited-Stage SCLC
3.
In a long-term comparison with adjuvant RT, salvage radiotherapy after prostateectomy is the most successful treatment.
4.
Early Identification of Ovarian Cancer; Allergy Medicine for NSCLC? Unfavorable Development for Anti-TIGIT Medication?
5.
Cancerous breast tissue glows in new AI-enhanced MRI images
1.
Precision Medicine and Genomics: Revolutionizing Healthcare Through Personalized Treatment
2.
The Benefits and Risks of Thrombolytics: A Comprehensive Guide
3.
Unveiling the Mystery of Epstein-Barr Virus: What We Know So Far
4.
A Closer Look at MCV Modules: Features, Functions, and Benefits
5.
From Bruises to Blood Clots: Everything You Need to Know about Hematoma
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Efficient Management of First line ALK-rearranged NSCLC - Part IV
2.
Learning About Different Treatment Approaches For Acute Lymphoblastic Leukemia
3.
A New Era in Managing Cancer-Associated Thrombosis
4.
Navigating the Complexities of Ph Negative ALL - Part XIV
5.
Expert Group meeting with the management of EGFR mutation positive NSCLC - Part IV
© Copyright 2025 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation